论文部分内容阅读
目的探讨绝经期促性腺激素及氯米芬在促排卵治疗中适宜的治疗方法。方法 2004年8月2008年5月对80例不孕患者实施促排卵治疗。测定血雌激素、黄体生成素水平、阴道B型超声、子宫颈黏液评分及基础体温测定监测排卵,并观察不良反应的发生情况。结果使用氯米芬及绝经期促性腺激素排卵率分别为77.3%和85.6%;卵巢过度刺激综合症发生率为15.0%,大多由使用绝经期促性腺激素方案引起,且起始剂量150U;未破裂卵泡黄素化综合征的发生率为9.0%。结论绝经期促性腺激素和氯米芬治疗排卵障碍性不孕有较好的疗效,绝经期促性腺激素和氯米芬促排卵治疗效果与卵巢的状态及激素水平有关。促性腺激素的使用应强调个体化,以达到较好的治疗效果并降低卵巢过度刺激综合症的发生。
Objective To investigate the appropriate treatment of menopausal gonadotropin and clomiphene in ovulation induction therapy. Methods August 2004 May 2008 80 cases of infertility patients to implement ovulation induction treatment. Measurement of blood estrogen, luteinizing hormone level, vaginal ultrasound B, cervical mucus score and basal body temperature to monitor ovulation, and to observe the occurrence of adverse reactions. Results Clomiphene and menopausal gonadotrophin ovulation rates were 77.3% and 85.6% respectively; the incidence of ovarian hyperstimulation syndrome was 15.0%, mostly caused by the use of menopausal gonadotropin regimen and the initial dose was 150U; The incidence of ruptured follicular luteinizing syndrome was 9.0%. Conclusions Menopausal gonadotropin and clomiphene are effective in the treatment of ovulatory dysplasia. The effect of menopausal gonadotropin and clomiphene on ovulation induction is related to ovarian status and hormone levels. The use of gonadotropin should emphasize individualization, in order to achieve better therapeutic effect and reduce the occurrence of ovarian hyperstimulation syndrome.